Join us for the final 2025–26 National #Thrombosis seminar: "Precision in DOAC reversal — a trainee-led UK network."
June 8, 12:00 ET | Featuring Dr Richard Buka !
Register to attend: https://t.co/4FyU19hC0U
#Anticoagulation#VTE#Research
The debate over DOAC selection just got clearer. 🔍
The #COBRRA trial provides a definitive head-to-head look at bleeding risks in #VTE. Tomorrow, we explore the findings!
Join the deep dive with @LanaCastellucci
Register to attend🔗 https://t.co/HdiDXD52Z8
#Research
Susan Kahn is a leading voice in venous thrombosis & its long-term complications. Her work has helped shape patient care and clinical practice globally. Now honored with the 2026 ISTH Esteemed Career Award, she reflects on her career: https://t.co/hkveUMn7wd
In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period. Full COBRRA trial results and Research Summary: https://t.co/tvPYrBCWj8
Dans le cadre d’une étude menée par la Dre Lana Castellucci, deux types d’anticoagulants souvent utilisés pour traiter la thromboembolie veineuse ont été comparés. L’un de ces médicaments a pu diminuer de plus de 50 % les cas d’hémorragie.
https://t.co/sHBPvlApo6
A study led by Dr. Lana Castellucci compared two types of anticoagulants commonly used to treat venous thromboembolism and showed that one of the medications reduced bleeding by more than 50%.
Learn more: https://t.co/IGN4Rev8Hr
#BloodClotAwarenessMonth
🐍 COBRRA trial finds ↓ clinically relevant bleeding with apixaban vs. rivaroxaban during the first 3 months of treatment for acute VTE (RR 0.46, 95% CI 0.33–0.65)🩸
@uOttawaMed@OttawaHospital@CIHR_IRSC@INVENT_VTE
In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period.
Full COBRRA trial results: https://t.co/tvPYrBCWj8
Excited to share this fantastic new tool from @ASH_hematology
https://t.co/px2XkLlTBD
TrialMap is the perfect resource for early-career clinician investigators. Guiding you from trial concept 💡 to practice-changing results 📄.
A must-bookmark if launching a clinical trial!
In ARTESiA:
Stroke ↓ 37%
Major bleeding ↑
Fatal & intracranial bleeding: similar
Understanding severity — not just frequency — changes the conversation.
New episode of CLOT Conversations: https://t.co/ikbqjDKbjp
#Anticoagulation#AFib#Thrombosis@DebSiegal
Can we safely rule out #DVT using age-adjusted D-dimer cutoffs? 🩺
Join our 1st 2026 Global Thrombosis Seminar! Dr. Grégoire Le Gal discusses the #ADJUST-DVT study (recently in @JAMA_current).
🗓️ Feb 25 🕘 14:00 UTC
🔗Register: https://t.co/fQr73UQQba
#VTE#MedEd#Research
‼️So exciting to have one of my #BantingCanada postdoc projects, published last year in the #EuropeanHeartJournal, recognized among the Top 10 Research Papers of 2025 in the field of #CardioOncology 🙏🏼🎉
https://t.co/YIsj0Hg7S9
📣 NEWS: The ISTH announces five global recipients of 2026 Esteemed Career Awards! This award honors leaders in thrombosis and hemostasis whose life-long achievements have shaped the field through scientific excellence.
Learn more: https://t.co/86YvNQvs34
Join us for our upcoming National #Thrombosis Seminar on "Periprocedural Anticoagulation Management for Central Line Insertion in Persons with Cancer."
Featuring: Dr. Jameel Abdulrehman - University of Toronto
📅 Feb 11 at 12:00 p.m. ET.
Register: https://t.co/7g0CbLIIrP
📢 Funding & Training Opportunities
Applications are OPEN for the Fall 2025 #CanVECTOR competitions:
✅ Pilot Study Funding ✅ Research Start-Up Awards ✅ Fellowships
PLUS: The Dr. Jack Hirsh Fellowship via @HamHealthSci & @McMasterU!
🔗 https://t.co/6ogszEjo4O
Join us today at 12pm ET for our next National Thrombosis Seminar on "Biomarkers & Genetics for the Prediction of #VTE & Clinically Relevant Bleeding in Cancer Patients" -
Featuring: Danielle Roy, PhD
Register: https://t.co/SZkCPqoEQQ
#Thrombosis#Research
🩺🧠 I will be chairing this Morning Report–style thrombosis cases, discussed live by an expert panel seeing the cases for the first time.
🎯 Perfect for thrombosis nerds
💻 Free & open to all. Register now! 👇
Hosted by @ThrombosisCan
🩸 #Thrombosis#MedEd
New CPD Webinar: Clinical Challenges in Thrombosis II
Live, unscripted cases. Real-time expert discussion.
March 3 | 7:00 PM ET
Register: https://t.co/M0O7voRZJh